Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 M IN PLASTIC CONTAINER versus TRAVASOL 5 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 M IN PLASTIC CONTAINER versus TRAVASOL 5 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
AMINOSYN 3.5% M IN PLASTIC CONTAINER vs TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% M is a mixture of essential and non-essential amino acids used for parenteral nutrition. It provides substrates for protein synthesis, thereby maintaining nitrogen balance and supporting tissue repair and growth.
Travasol 5.5% with electrolytes provides a source of amino acids and electrolytes for parenteral nutrition, supporting protein synthesis and maintaining metabolic balance.
Intravenous infusion: 500 mL to 1 L of 3.5% amino acid solution per day for adults; rate not to exceed 0.1 g amino acids/kg/hr.
Intravenous: 500 mL to 2 L per day, infused at a rate of 20-40 mL/kg/day (0.5-1.5 g amino acids/kg/day) based on metabolic needs and tolerance.
None Documented
None Documented
Variable (minutes to hours) due to rapid metabolic utilization; terminal half-life in plasma is <10 minutes for most amino acids.
Not applicable; components are endogenous and rapidly cleared. Amino acids have short half-lives (e.g., alanine ~15 min; leucine ~30 min) and are continuously metabolized. Terminal elimination of water and electrolytes follows body fluid kinetics.
Renal: >90% as amino acids and metabolites; negligible biliary/fecal elimination.
Primarily renal; 90-100% eliminated as free amino acids, electrolytes, and water. Metabolized nitrogen is excreted as urea. Biliary/fecal: negligible (<2%).
Category C
Category C
Amino Acid Solution
Amino Acid Solution